VitalHub: The Margin Snap-Back Meets the Palantir Clause
Recurring revenue crossed 81% of the mix and adjusted EBITDA hit a two-year high — but a ~7% slice of ARR in the U.K. now hangs on an NHS decision management refuses to size.
VHI.TO · Earnings Call · 2026-11-13
The optics problem: flat headline, better business
On the surface, VitalHub's Q3 2026 looks like a stall: total revenue of $31.9 million arrived flat year-over-year. Look underneath and the mix has quietly improved. Recurring revenue — term license, maintenance and support — was $25.8 million, or 81% of the total, up from $23.6 million and 74% a year ago. The flat top line is an artifact of the two lumpy pieces: perpetual license revenue collapsed to $100,000 from $500,000, and services/hardware fell to $3.7 million from $5.5 million as the summer quarter came in light on revenue recognition. Management is adamant this is timing, not deterioration. “our backlog for our services revenue has never been stronger. It was just the case of getting it into the revenue recognition state, and that tends to be lumpy.” — Daniel Matlow, Chief Executive Officer · 2026-11-13 The payoff showed up on the bottom line: adjusted EBITDA of $8.6 million (27% of revenue, versus $7.2 million / 22% prior year) was the highest margin in the last two years, and net income swung to $2.6 million from a $900,000 loss. Nine-month operating cash flow of $23.9 million was up 69%, against a balance sheet holding $129 million of cash and short-term investments with no debt. Whatever the revenue optics say, the cash machine is running.SHREWD: the recurring overhang with a hard deadline
The word dominating this quarter's keyword set is SHREWD scenario — VitalHub's U.K. business that sits inside the NHS's Federated Data Platform ecosystem, tied to Palantir. It is roughly 7–8% of ARR, or about $10 million in Dan Matlow's estimate, and the situation is fluid in the worst way: customers suspending, some un-suspending, renewals flipping by the week. When analysts pressed for the range of outcomes, Matlow declined to draw the map:The genuinely new catalyst is a contractual clock. Matlow pointed to a break clause in the Palantir contract exercisable in February 2027: “They have a break clause in their contract for February of 2027 that they can exercise on the Palantir product.” — Daniel Matlow, Chief Executive Officer · 2026-11-13 That decision — extend, transition away, or muddle through — is the swing factor for whether VitalHub returns to Rule-of-40 economics in 2027. Crucially, this is not a new theme. The prior call (2026-08-07) was already deep in it, with Doug Taylor asking directly “with the impact of Schreud, some of the pause that you're talking about. Is that something that is reflected in the net ARR growth?” — Analyst Doug Taylor, Analyst · 2026-08-07 and Matlow conceding “we definitely took some AR reduction in the quarter with some of the Schreud work.” — Daniel Matlow, CEO · 2026-08-07 What has changed is the specificity: the ~7–8% ARR figure is now on the record, and the February 2027 deadline turns a vague "wait and see" into a dated event.I'm reluctant to give out the exact numbers because they change literally by the week... if we didn't have the suspensions or the reversals on some of those SHREWD cuts, we would have been very close to our Rule of 40 base level.